Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04214249
Title BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

acute myeloid leukemia

Therapies

Cytarabine + Daunorubicin

Cytarabine

Cytarabine + Idarubicin

Pembrolizumab

Cytarabine + Daunorubicin + Pembrolizumab

Cytarabine + Pembrolizumab

Cytarabine + Idarubicin + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST